Global molecular diagnostics company Genetic Signatures (ASX: GSS) has decided to halt the development of its EasyScreen Essentials Respiratory Detection Kit for the US market due to increased competition and changing market dynamics. It will now focus its effort and investment on the anticipated launch of the EasyScreen Gastrointestinal Parasite Detection Kit in the US.
Read More
Molecular diagnostics company Genetic Technologies (ASX: GTG) is piloting its risk assessment test geneType in breast screening centres across the US. The Company is establishing a clinical implementation study with breast imaging centres in New York, Miami and Houston. In the US, screening is currently between the ages of 40 and 74. So, the current
Read More